论文部分内容阅读
观察康妇炎胶囊联合抗生素治疗对慢性盆腔炎患者临床疗效及炎症因子水平影响,指导临床治疗与用药。方法:医院2015年1月—2016年3月妇科门诊及病房收治的慢性盆腔炎患者74例随机分为观察组和对照组,每组37例,对照组采用抗生素治疗,观察组采用康妇炎胶囊+抗生素治疗,两组患者均治疗14 d。治疗后观察两组患者临床疗效,记录治疗前后血清中IL~(-1)(白介素-1)、IL-2(白介素-2)浓度表达情况及不良反应发生情况。结果:治疗后,观察组患者总缓解率94.59%,对照组的总缓解率为86.49%,观察组总缓解率显著高于对照组,差异具有统计学意义(P<0.05)。与治疗前比较,两组患者IL~(-1)表达水平均降低,IL-2表达均升高,差异具有统计学意义(均P<0.05);治疗后组间比较,观察组患者IL~(-1)及IL-2改善幅度由于对照组,差异具有统计学意义(均P<0.05)。观察组患者食欲不振、恶心、嗜睡及头晕发病率与对照组水平相当,差异不具有统计学意义(均P>0.05)。治疗前后两组患者血常规、生化指标变化差异均无统计学意义(P>0.05)。结论:对慢性盆腔炎患者在抗生素治疗基础上加用康妇炎胶囊能够提高临床疗效,调整致炎和抗炎的动态平衡,且安全可靠,值得临床推广使用。
To observe the effect of Kang Fuyan Capsule combined with antibiotics on clinical efficacy and inflammatory cytokines levels in patients with chronic pelvic inflammatory disease and to guide clinical treatment and medication. Methods: From January 2015 to March 2016, 74 patients with chronic pelvic inflammatory disease admitted to gynecology clinic and ward were randomly divided into observation group and control group, with 37 cases in each group. The control group was treated with antibiotics. The observation group was given Kang Fu Yan Capsule + antibiotic treatment, both groups were treated for 14 days. After treatment, the clinical efficacy of the two groups were observed. The levels of IL-1, IL-2 and IL-2 in serum before and after treatment were recorded and the incidence of adverse reactions were recorded. Results: After treatment, the total remission rate was 94.59% in the observation group and 86.49% in the control group. The total remission rate in the observation group was significantly higher than that in the control group (P <0.05). The levels of IL-1 and IL-2 in both groups were significantly lower than those before treatment (all P <0.05). After treatment, the levels of IL- (-1) and IL-2 improvement rate due to the control group, the difference was statistically significant (P <0.05). The incidence of loss of appetite, nausea, drowsiness and dizziness in the observation group were comparable to those in the control group, with no significant difference (all P> 0.05). There was no significant difference in blood routine and biochemical indexes between the two groups before and after treatment (P> 0.05). Conclusion: The treatment of chronic pelvic inflammatory disease in patients with Kang Fu Yan capsule based on the treatment can improve clinical efficacy, adjust the dynamic balance of pro-inflammatory and anti-inflammatory, and safe and reliable, worthy of clinical promotion and use.